Investigational New Drugs Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

IND Application Submitted to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
CAMBRIDGE, Mass., Dec. 28, 2023. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has submitted an Investigational New Drug (IND) application to the U.S.... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 28, 2023 Category: Pharmaceuticals Source Type: clinical trials

Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China
SHANGHAI, Dec. 3, 2023. Everest Medicines ( " Everest " , or the " Company " ), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced that China National Medical... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 4, 2023 Category: Pharmaceuticals Source Type: clinical trials

FDA Clears Application to Initiate Phase 1 Clinical Study of oral Immunotherapy for the Treatment of Rheumatoid Arthritis
ROCKVILLE, Md., Oct. 19, 2023. - Rise Therapeutics, a biotechnology company engaged in developing novel oral immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND)... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 20, 2023 Category: Pharmaceuticals Source Type: clinical trials

PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
Safety, transcript splicing and clinical outcome measures data at 5 mg/kg PGN-EDODM1 dose level in patients from FREEDOM-DM1 clinical study expected in 2024 Continue to expect safety, muscle exon skipping and dystrophin data at 5 mg/kg PGN-EDO51... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 12, 2023 Category: Pharmaceuticals Source Type: clinical trials

Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors
SINGAPORE, Sept. 12, 2023. On September 9th, 2023, Biosyngen Pte Ltd announced that the U.S. FDA has cleared the Investigational New Drug (IND) application for Phase I/II clinical trial of BRL03 for the treatment of lung cancer, gastric cancer... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 11, 2023 Category: Pharmaceuticals Source Type: clinical trials

Mebias Discovery Initiates a Phase I Clinical Trial of MEB-1170, a Novel Analgesic Drug Candidate for the Treatment of Pain and Prevention of Opioid Use Disorder
Philadelphia, PA, November 29, 2022– Mebias Discovery Inc., a biotechnology company focused on drug discovery targeting G-protein coupled receptors, today announces its Investigational New Drug, MEB-1170, has entered Phase I human clinical... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 29, 2022 Category: Pharmaceuticals Source Type: clinical trials

STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
Condition: Spinocerebellar Ataxia Type 3 Interventions: Drug: SLS-005; Drug: Placebo Sponsor: Seelos Therapeutics, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2022 Category: Research Source Type: clinical trials